PrimeRFP SCOUT · Federal Contract Recompete Brief

75N90026F00006F-18) pylarify (piflufolastat FROM progenics — Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79725D0093. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health - Cc
Awarding office
Progenics Pharmaceuticals Inc
Recipient
Sep 30, 2026
PoP end
$886K
Obligated
$529K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Progenics Pharmaceuticals Inc — $90

Contract facts

Federal
Contract number75N90026F00006
Also listed as36F79725D0093-75N90026F00006
AgencyNational Institutes Of Health - Cc
Awarding officeNational Institutes Of Health - Cc
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentProgenics Pharmaceuticals Inc
CAGE34KE9
UEIYLYKVRPCTCR3
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79725D0093
Place of performanceNORTH BILLERICA MA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
Related solicitationNOI-CC-26-000012
PoP startOct 1, 2025
PoP end (current)Sep 30, 2026
Obligated$886K
Current value$886K
Potential value$529K

PYLARIFY (PIFLUFOLASTAT F-18) FROM PROGENICS PHARMACEUTICALS INC.:1106332 [26-000012] is a federal award for National Institutes Of Health - Cc held by Progenics Pharmaceuticals Inc. Estimated value $529K ($886K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: NORTH BILLERICA MA. Related solicitation NOI-CC-26-000012.

PYLARIFY (PIFLUFOLASTAT F-18) FROM PROGENICS PHARMACEUTICALS INC.:1106332 [26-000012]

Recompete timing

Public
Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Progenics Pharmaceuticals Inc$95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies
Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C24625N1142
PYLARIFY F-18 INJECTIONS (336)
$1.2M
Aug 31, 2026
75N90025F00021
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO.:1108959 [25-004297]
$611K
Sep 25, 2026
36C26126N0023
480 F18 PYLARIFY DOSES POP 1/1/2025 - 12/31/2025
$1.7M
Sep 26, 2026
75N90025F00003
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]
$2.1M
Sep 29, 2026
36C26122N0385
PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01
$4.5M
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75N90026F00006?

75N90026F00006 (F-18) pylarify (piflufolastat FROM progenics) is a National Institutes Of Health - Cc award with a potential value of $529K, currently held by Progenics Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N90026F00006?

National Institutes Of Health - Cc awarded 75N90026F00006 to Progenics Pharmaceuticals Inc (potential $529K).

Who is the incumbent on 75N90026F00006?

Progenics Pharmaceuticals Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Progenics Pharmaceuticals Inc’s 75N90026F00006 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N90026F00006